News|Videos|November 18, 2026
How Atopic Dermatitis May Affect Growth and Bone Health in Children
Author(s)Lisa Swanson, MD, FAAD
Lisa Swanson, MD, explores how pediatric atopic dermatitis, sleep disruption, and dupilumab may influence growth and bone health
Advertisement
Episodes in this series



For children with moderate to severe atopic dermatitis (AD), the burden of disease can extend well beyond persistent inflammation, pruritus, and visible skin lesions. Increasing attention is being directed toward the potential effects of chronic disease activity on pediatric growth and bone health, particularly as emerging research examines the relationship between AD, sleep disruption, corticosteroid exposure, and growth-related biomarkers.
In a Dermatology TimesExpert Perspectives series titled Beyond the Skin: Sleep, Steroids, and Growth in Children With Atopic Dermatitis, Lisa Swanson, MD, explores how clinicians can approach concerns about growth and bone health in pediatric patients with AD. The discussion examines the potential consequences of uncontrolled disease, the role of sleep in healthy development, and emerging evidence surrounding dupilumab (Dupixent) and growth-related outcomes.
Although biologic therapies have expanded treatment options for younger patients with moderate to severe AD, questions remain about how improved disease control may influence growth trajectories and markers of bone formation. Understanding these relationships may help clinicians address parental concerns and incorporate broader developmental considerations into long-term disease management
Looking Beyond Skin Symptoms in Pediatric AD
Children with severe AD frequently experience persistent itching, sleep disturbances, and substantial impairment in daily functioning. Although these consequences are well recognized, their potential implications for physical growth and skeletal development have received increasing attention
Growth concerns are particularly relevant for children with longstanding, poorly controlled disease or those already tracking at lower percentiles on standardized growth charts. In these patients, clinicians must consider whether observed growth patterns reflect underlying disease burden, treatment exposure, individual developmental variation, or a combination of factors
The relationship between AD and growth is complex, and available evidence does not establish a single mechanism responsible for differences in height or bone-related outcomes. Nevertheless, observational research has suggested an association between pediatric AD and shorter stature
A 2025 retrospective cohort analysis using the TriNetX database found that children with AD had a higher risk of height below the fifth percentile compared with matched controls (relative risk, 1.15; 95% CI, 1.12-1.18). Although the findings suggest a potential relationship between AD and growth outcomes, the observational design limits conclusions about causality
For clinicians, these findings reinforce the importance of evaluating growth within the broader context of disease severity, symptom burden, treatment history, and overall pediatric health
The Relationship Between Itch, Sleep, and Growth
Sleep disruption is among the most significant consequences of pediatric AD, particularly in children experiencing persistent nocturnal pruritus. Repeated nighttime awakenings and difficulty maintaining restorative sleep can affect both children and their families, contributing to fatigue and reduced quality of life
Beyond these immediate consequences, sleep is closely connected to physiological processes involved in childhood growth. Growth hormone secretion is associated with sleep, and normal sleep patterns contribute to processes involved in bone development and remodeling
This relationship has prompted researchers to investigate whether improvements in AD symptoms, particularly itch and sleep disturbance, could have downstream implications for growth-related outcomes
In the Expert Perspectives discussion, Swanson addresses how clinicians can evaluate sleep disturbances alongside growth concerns when caring for children with severe AD. Rather than viewing these issues as unrelated consequences of chronic skin disease, the discussion emphasizes the importance of considering how persistent symptoms may interact with broader developmental health
Assessing sleep quality, nighttime itching, and changes in daily functioning may provide additional clinical context when evaluating the overall burden of AD. Growth monitoring, meanwhile, remains important for identifying children whose height trajectories warrant further assessment
Could Dupilumab Influence Growth-Related Outcomes?
Emerging research has raised questions about whether effective systemic treatment of AD may be associated with improvements in growth-related measures
A 2026 post hoc analysis discussed in the series examined height outcomes and bone alkaline phosphatase (BALP), a biomarker associated with bone formation, among children receiving dupilumab for severe AD
The investigators proposed that improvements in itch and disease control could indirectly influence growth-related outcomes through better sleep. However, sleep was not directly measured in the analysis, making this proposed pathway a hypothesis rather than a demonstrated mechanism
This distinction is important when interpreting the findings. Although changes in BALP may provide information about bone formation activity, the biomarker does not directly measure bone mineral density or establish improvements in long-term skeletal health
Similarly, changes in height percentiles may offer insight into growth trajectories but require interpretation alongside age, baseline growth patterns, treatment duration, and other potential influences
The available findings therefore raise clinically relevant questions about the broader effects of controlling severe AD without establishing that dupilumab directly improves bone density or stimulates growth
Incorporating Growth and Sleep Into Clinical Conversations
For families managing severe pediatric AD, questions about long-term development can add another layer of concern to an already challenging treatment experience. Parents may wonder whether persistent inflammation, inadequate sleep, or medications could influence their child’s eventual height or skeletal health
Addressing these concerns requires clinicians to distinguish between established evidence, emerging associations, and questions that remain unanswered
Routine assessment of growth patterns, discussion of sleep quality, and evaluation of disease control may help clinicians identify concerns that deserve closer attention. For children with persistent growth abnormalities, collaboration with pediatricians or other specialists may also be appropriate
Importantly, the potential relationship between AD and growth should not be interpreted as evidence that all children with the condition will experience impaired development. Instead, it highlights the value of individualized assessment, particularly in patients with severe or inadequately controlled disease
As research continues to clarify the relationship between inflammation, sleep, treatment response, and skeletal development, these considerations may become increasingly relevant to comprehensive pediatric AD management
Advertisement
Related to this article
View more
Advertisement
Advertisement
Trending on Dermatology Times
12345


